Alvogen announced to acquire Dream Pharma with 194.5 billion won in cash through its subsidiary Kunwha Pharmaceutical

Published: 2014-08-08 09:04:28

Updated: 2014-08-08 09:04:28

Alvogen announced that they confirmed to acquire Dream Pharma with 194.5 billion won in cash through its subsidiary company Kunwha Pharmaceutical. The official procedure is expected to be completed in the fourth quarter of 2014.

Dream Pharma along with Kunwha Pharmaceutical become able to enhance its market competitiveness with the network utilization in 11 countries in Asia from Alvogen. Alvo...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.